Therapie最新文献

{"title":"Livre blanc de la pharmacologie biologique","authors":"Florian Lemaitre ,&nbsp;Caroline Monchaud ,&nbsp;Matthieu Grégoire ,&nbsp;Romain Guilhaumou ,&nbsp;Françoise Goirand ,&nbsp;groupe de travail « Suivi thérapeutique pharmacologique et personnalisation des traitements de la Société française de pharmacologie et de thérapeutique »","doi":"10.1016/j.therap.2025.10.002","DOIUrl":"10.1016/j.therap.2025.10.002","url":null,"abstract":"<div><div>En 2024, le groupe de travail « Suivi thérapeutique pharmacologique et personnalisation des traitements de la Société française de pharmacologie et de thérapeutique » a élaboré un livre blanc dont l’objectif est de présenter l’état des lieux de la sous-discipline de la pharmacologie biologique, de décrire les compétences attendues pour exercer le métier de pharmacologue biologiste, de définir le périmètre de l’activité professionnelle, d’identifier les forces et les points d’amélioration actuels de la sous-discipline dans l’objectif final de proposer les évolutions du métier de pharmacologue biologiste. Ce document se compose de plusieurs parties : un préambule visant à rappeler le panorama de la pharmacologie biologique en France ; un état des lieux rappelant ce qu’est un pharmacologue biologiste, ses missions, les forces et faiblesses de la profession et les pré-requis en termes de formation ; un référentiel de compétences du pharmacologue biologiste et enfin les perspectives et nouvelles missions du pharmacologue biologiste. Ce document a pour vocation de servir de référentiel, d’aider à définir la profession de pharmacologue biologiste et de structurer la discipline afin de pouvoir la faire évoluer vers une profession d’interface entre biologie et clinique.</div></div><div><div>In 2024, the therapeutic drug monitoring and treatment personalization working group of the Société française de pharmacologie et de thérapeutique (French Society of Pharmacology and Therapeutics) drew up a white paper, the aim of which is to present the current state of the biological pharmacology discipline, describe the skills required to exercise the profession, define the scope of professional activity, identify the discipline's current strengths and areas for improvement, with the ultimate aim of proposing changes to the profession of biological pharmacologist. This document is divided into several parts: a preamble outlining the panorama of biological pharmacology in France; a review of the current situation, outlining what a pharmacological biologist is, his or her missions, the strengths and weaknesses of the profession, and the prerequisites in terms of training; a reference framework of competencies for the pharmacological biologist; and, finally, the prospects and new missions of the pharmacological biologist. The purpose of this document is to serve as a term of reference, to help define the profession of pharmacological biologist, and to structure the discipline so that it can evolve into a profession at the interface between biology and the clinic.</div></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"80 6","pages":"Pages 681-688"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145610242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thanks to reviewers","authors":"","doi":"10.1016/S0040-5957(25)00150-7","DOIUrl":"10.1016/S0040-5957(25)00150-7","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"80 6","pages":"Pages 698-699"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145610243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analyse de la déclaration de pharmacovigilance par les chirurgiens-dentistes en France : bilan des 10 dernières années","authors":"Antonin Vagnet ,&nbsp;Hélène Peyrouzet ,&nbsp;Viktoryia Prontskus ,&nbsp;Corinne Guihard ,&nbsp;Lucie Vettoretti ,&nbsp;Marie Blanche Valnet Rabier","doi":"10.1016/j.therap.2025.02.011","DOIUrl":"10.1016/j.therap.2025.02.011","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Les chirurgiens-dentistes, dans l’exercice de leur profession, assument la responsabilité tant du bénéfice que du risque associé aux médicaments qu’ils prescrivent. Leur code de déontologie, leur accorde une liberté dans leurs prescriptions tout en les incitant à limiter leurs interventions aux seuls besoins nécessaires à la qualité et à l’efficacité des soins. De plus, les chirurgiens-dentistes sont également confrontés aux effets indésirables odontologiques résultant de médicaments qu’ils n’ont pas eux-mêmes prescrits. Une étude basée sur l’analyse des cas enregistrés sur dix ans dans la base nationale de pharmacovigilance (BNPV) se révèle pertinente pour dresser un état des lieux de la déclaration de pharmacovigilance émanant des chirurgiens-dentistes.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;Nous avons réalisé une analyse rétrospective des cas enregistrés dans la BNPV déclarés par les chirurgiens-dentistes entre le 01/01/2013 et le 31/12/2023.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Sur une période de 10 ans, 509 signalements ont été rapportés, représentant 0,06 % de l’ensemble des cas enregistrés. Ces signalements ont été répartis en trois groupes principaux. Parmi ces 509 déclarations, 24,8 % sont des cas associés à des médicaments utilisés dans le domaine de l’odontologie, comme les anti-inflammatoires, les antibiotiques, les anesthésiques locaux ou encore les antiseptiques locaux ; 35,2 % sont des cas d’effets indésirables odontologiques comme les ostéonécroses de la mâchoire, les hypertrophies gingivales et les ulcérations buccales. Enfin, 28,3 % des cas concernent des déclarations d’effets indésirables en lien avec la vaccination &lt;em&gt;coronavirus disease&lt;/em&gt; 2019 (COVID-19) débutée fin décembre 2020.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Le faible taux de déclarations de pharmacovigilance par les chirurgiens-dentistes en France au cours des dix dernières années met en évidence un problème de sous-déclaration des effets indésirables dans la pratique dentaire. Les données récentes de la littérature soulignent l’importance de la déclaration de pharmacovigilance dans le domaine de l’odontologie, notamment sur les effets odontologiques.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Dentists, in their practice, bear responsibility for the benefits and the risks associated with the medications they prescribe. Their code of ethics grants them the freedom to prescribe while encouraging them to limit their interventions to what is strictly necessary for the quality and effectiveness of care. Furthermore, dentists also face ontological adverse effects resulting from medications they did not personally prescribe. A study based on the analysis of cases recorded over ten years in the national pharmacovigilance database (BNPV) is relevant for assessing the current state of pharmacovigilance reports submitted by dentists.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;We conducted a retrospective analysis of the cases recorded in the BNP","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"80 6","pages":"Pages 647-652"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143721561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The French IRB Study : qualification des recherches soumises aux comités d’éthique","authors":"Charles-Hervé Vacheron ,&nbsp;Arnaud Friggeri ,&nbsp;Maxime Lambert ,&nbsp;Laura Shoonjans ,&nbsp;Philippe Amiel","doi":"10.1016/j.therap.2025.05.002","DOIUrl":"10.1016/j.therap.2025.05.002","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objectifs&lt;/h3&gt;&lt;div&gt;En France, les « recherches impliquant la personne humaine » (RIPH), définies au Code de la santé publique, sont examinées par des « comités de protection des personnes » (CPP) institués par la loi. Les autres recherches, sont évaluées par des « comités d’éthique de la recherche » (CER) qui peuvent être installés par des institutions de recherche (instituts, hôpitaux, universités…) sans cadre légal défini. La qualification de la recherche comme RIPH ou « non-RIPH » (RNIPH) détermine la filière d’évaluation – légale obligatoire ou extra-légale. Notre objectif a été de décrire la performance des CER et CPP à qualifier les projets de recherche en RIPH ou RNIPH, le standard de qualification utilisé étant le « Guide de la qualification des recherches en santé », référentiel de l’Institut national de la santé et de la recherche médicale (Inserm) publié en 2021.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;La liste des CPP étant connue par ailleurs, les universités, centres hospitaliers universitaires et sociétés savantes de spécialités médicales ont été contactés pour savoir s’ils abritaient un CER. Entre le 29/01/2024 et le 29/02/2024, tous les CPP et CER documentés ont été sollicités pour participer à l’étude. En cas d’acceptation, un mail était envoyé aux membres vers un questionnaire en ligne proposant quatre cas à qualifier, soit en RIPH, soit en non-RIPH. Les cas étaient tirés des exemples fournis par le guide de l’Inserm, qui a servi également de référentiel pour apprécier les réponses. L’analyse des réponses a été réalisée individuellement et à l’échelle de chaque comité participant.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Trente-cinq (35) centres, sur les 110 contactés, ont participé produisant 175 réponses individuelles récoltées. Le nombre de membres par comité était de 18 [12–23]. Le taux de réponse par comité était de 27 % [14–47]. Concernant les réponses des membres, la qualification pour les quatre cas était conforme à celle du guide de l’Inserm dans 79 % (138), 62 % (108), 66 % (116), et 61 % (106) des cas. À l’échelle des comités, une large disparité entre les différents centres a été documentée, sans différences notables entre CER et CPP.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Une forte hétérogénéité de la qualification des recherches a été notée entre les différents comités, sans rapport avec le type de structure (CER ou CPP). Des dispositifs d’information et de formation, visant tous types de comités, devraient être encouragés pour uniformiser l’étape de la qualification des recherches.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;In France, the “Research investigations involving human subjects” (RIPH), defined in the Public Health Code, are reviewed by “committees for the protection of persons” (CPP) established by law. Other research studies in health are evaluated conducted by “research ethics committees” (CER) that can be established by research institutions (institutes, hospitals, universities, etc.) without a d","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"80 6","pages":"Pages 631-638"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"L’inobservance précoce des anticancéreux oraux, un enjeu primordial de pharmacie clinique en onco-sénologie","authors":"Fanny Leenhardt ,&nbsp;Pauline Ares ,&nbsp;Alma Nicolai ,&nbsp;Cécile Corbinais ,&nbsp;Marie Viala ,&nbsp;Véronique d’Hondt ,&nbsp;François Jouvet ,&nbsp;Frédéric Pinguet","doi":"10.1016/j.therap.2025.06.001","DOIUrl":"10.1016/j.therap.2025.06.001","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;L’évaluation de l’observance est nécessaire pour s’assurer de l’adhésion thérapeutique, particulièrement avec les anticancéreux oraux (ACO). Bien que facilement réalisable, le questionnaire national validé GIRERD semble incomplet pour l’évaluer. Nous avons voulu étudier et caractériser l’observance dans une cohorte de patientes traitées par ACO à l’aide de 2 questionnaires.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Matériel et méthodes&lt;/h3&gt;&lt;div&gt;L’évaluation a été conduite chez des patientes traitées par ACO à l’aide du questionnaire GIRERD, constitué de 6 items et un questionnaire institutionnel constitué de 7 items ; avec une gradation commune basée sur celle du score GIRERD. Ces questionnaires ont été soumis dans les 3 premiers mois d’initiation du ribociclib, chez des femmes atteintes d’un cancer du sein hormono-dépendants métastatiques.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Parmi les 50 patientes évaluables, environ 60 % ont un score supérieur à 0 (faiblement observant [FO]&lt;!--&gt; &lt;!--&gt;+&lt;!--&gt; &lt;!--&gt;non-observant [NO]) selon les 2 questionnaires à l’étude. Les patientes NO représentent 6 % selon le score GIRERD et 16 % selon le score institutionnel. Les principales causes d’inobservance étaient le retard sur l’horaire de prise (21/50) et l’oubli de l’ACO lors de déplacement (13/50) ; 54 % des patientes ayant une aide à la prise d’ACO (pilulier…) s’avèrent inobservantes.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Discussion&lt;/h3&gt;&lt;div&gt;Plus de la moitié des patientes ont présenté au moins un évènement d’inobservance dans les 3 premiers mois de l’ACO, indiquant une nécessité de sécuriser la mise en route de ces traitements. L’observance doit être évaluée avec des outils pertinents. Le score institutionnel intercepte finalement plus d’inobservance franche alors que le score GIRERD sous-évaluerait l’inobservance au sein de notre cohorte.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Les patientes de notre cohorte apparaissent pour plus de la moitié d’entre elles faiblement observantes de manière précoce, et cela quel que soit le score d’évaluation. Cette évaluation de l’observance constitue une étude de faisabilité de l’utilisation de notre questionnaire en routine clinique dans le suivi des patients recevant un ACO.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;The assessment of adherence is necessary to ensure therapeutic compliance, particularly with oral anti-cancer drugs (OACs). Already easily implemented, the nationally validated GIRERD questionnaire seems incomplete for assessing adherence. We set out to study and characterize adherence in a cohort of patients treated with OACs, using 2 questionnaires.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Material and methods&lt;/h3&gt;&lt;div&gt;The evaluation was carried out in patients treated with OAC using the GIRERD questionnaire, composed of 6 items, and an institutional questionnaire consisting of 7 items; with a common gradation based on that of the GIRERD score. These questionnaires were submitted within the first 3 months of ribociclib (OAC) initiation,","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"80 6","pages":"Pages 653-659"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood glutamate levels in major depression with antidepressants and benzodiazepines: A 6-month prospective cohort study","authors":"Khalil El Asmar ,&nbsp;Tala El Ghoul ,&nbsp;Romain Colle ,&nbsp;Rida Assaf ,&nbsp;Séverine Martin ,&nbsp;Séverine Trabado ,&nbsp;Bruno Feve ,&nbsp;Céline Verstuyft ,&nbsp;Laurent Becquemont ,&nbsp;Emmanuelle Corruble","doi":"10.1016/j.therap.2025.04.003","DOIUrl":"10.1016/j.therap.2025.04.003","url":null,"abstract":"<div><h3>Aim of the study</h3><div><span>Our study aims at analyzing blood glutamate levels at three time points in patients on antidepressants and </span>benzodiazepines across different subgroups.</div></div><div><h3>Methods</h3><div><span>In the 6-month METADAP cohort study, blood glutamate levels were measured in 60 patients with major depression at baseline, 3 months (M3), and 6 months (M6) after starting antidepressant treatment. All patients received a co-prescription with </span>benzodiazepines. Mixed-effect linear regression models were used to analyze the correlation of glutamate levels over time among responders, non-responders, remitters, and non-remitters, adjusting for multiple confounders.</div></div><div><h3>Results</h3><div>Glutamate blood levels showed a significant decrease. Glutamate levels decreased from M0 to M3 across all subgroups. Responders and remitters showed a further decline from M3 to M6 while they increased non-significantly from M3 to M6 among non-responders and non-remitters. Responders showed a decrease of 3.38<!--> <!-->μmol/L [95% CI (−4.94; −1.82), <em>P</em> <!-->&lt;<!--> <!-->0.001], while remitters showed a decrease of 1.34<!--> <!-->μmol/L [95% CI (−2.41; −0.27), <em>P</em> <!-->=<!--> <!-->0.014].</div></div><div><h3>Conclusion</h3><div>Glutamate blood levels decreased from M0 to M3 across all groups but varied from M3 to M6: responders and remitters continued to decline, while non-responders and non-remitters showed a non-significant increase. These results should be replicated and further explained.</div></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"80 6","pages":"Pages 625-630"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of thiopurines therapeutic drug monitoring in patients with inflammatory bowel disease","authors":"Zohra Chadli ,&nbsp;Ibtissem Hannachi ,&nbsp;Nadia Ben Fredj ,&nbsp;Hichem Loghmari ,&nbsp;Haifa Ben Romdhane ,&nbsp;Ahlem Slama ,&nbsp;Amel Chaabane ,&nbsp;Leila Safer ,&nbsp;Karim Aouam","doi":"10.1016/j.therap.2025.03.001","DOIUrl":"10.1016/j.therap.2025.03.001","url":null,"abstract":"<div><h3>Introduction</h3><div><span>Thiopurine drugs, the most commonly prescribed </span>immunosuppressive agents<span><span> used in the treatment of inflammatory bowel disease<span> (IBD), are characterized by a narrow therapeutic window, which makes </span></span>therapeutic drug monitoring<span><span> (TDM) of thiopurine metabolites recommended. 6-thioguanine nucleotides (6-TGN) are considered the most active metabolites of the thiopurines and they are responsible for therapeutic efficacy and correlate with </span>myelotoxicity. This present study aims to assess the usefulness of 6-TGN monitoring in Tunisian patients with IBD.</span></span></div></div><div><h3>Patients and methods</h3><div><span>We performed a retrospective study including patients with IBD treated by azathioprine and underwent a TDM of 6-TGN between May 2018 and December 2023. Samples of venous blood were collected at 2</span> <!-->hours after medication intake. Concentrations values were determined, at the steady-state, using a technique of High-performance liquid chromatography (HPLC). Correlations between the 6-TGN concentrations and hematological parameters were assessed by Pearson's correlation coefficient.</div></div><div><h3>Results</h3><div>A total of 140 patients were included (65 men/75 women). The average concentration was 386.2<!--> <!-->±<!--> <!-->258.9<!--> <!-->pmol/8<!--> <!-->×<!--> <!-->10⁸ RBCs. After an initial dose, only 49% of the patients had 6-TGN concentrations in the target range. The multiple TDM after AZA dose adjustment has shown improvement of the probability of obtaining 6-TGN concentration in the target range (69%). In our study, we demonstrated that 6-TGN concentrations were inversely correlated with hemoglobin levels, white cell, and neutrophil counts.</div></div><div><h3>Conclusion</h3><div>We have shown the usefulness of AZA TDM by determining the 6-TGN metabolite concentrations in Tunisian patients. However, this approach remains insufficient to optimize the treatment by azathioprine. Other approaches, such as genotyping patients for TPMT and NUD15 and adjusting AZA doses based on population pharmacokinetic models, appear to be essential for optimizing AZA therapy.</div></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"80 6","pages":"Pages 673-680"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients under treatment for sarcoidosis reported adherence issues and would welcome personalized pharmaceutical care: Results from survey online","authors":"Cléa Dubrou ,&nbsp;Dorian Protzenko ,&nbsp;Aurélie S. Leroyer ,&nbsp;Raphael Cauchois ,&nbsp;Gilles Kaplanski ,&nbsp;Guillaume Hache","doi":"10.1016/j.therap.2025.05.001","DOIUrl":"10.1016/j.therap.2025.05.001","url":null,"abstract":"<div><div><span>Sarcoidosis<span> is an immune-inflammatory condition marked by significant health disparities<span>. Around 50% of individuals diagnosed with sarcoidosis need long-term or even lifelong treatment to halt the progression of the disease. Recent guidelines, primarily targeting pulmonary sarcoidosis<span>, have been proposed. Despite this, reports on medication adherence in sarcoidosis are scarce, and pharmaceutical care is rarely incorporated into patient-centered treatment strategies. In our study, we conducted a survey through social media (</span></span></span></span><em>n</em> <!-->=<!--> <span>157) and discovered that 79% of participants were either slightly or not at all adherent to their medication regimen, according to the Girerd score. The primary goal of this project is to pinpoint the factors influencing non-adherence among sarcoidosis patients. We identified that treatment involving corticosteroids or corticosteroid-sparing drugs, coupled with factors like age and pulmonary localization, are linked to poorer adherence outcomes. Moreover, patients demonstrating poor adherence showed a readiness to engage in personalized pharmaceutical care.</span></div></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"80 6","pages":"Pages 660-666"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144133244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drugs and patient's dissatisfaction reporting: From a disproportionality pharmacovigilance analysis to social pharmacology","authors":"Jean-Louis Montastruc","doi":"10.1016/j.therap.2025.04.005","DOIUrl":"10.1016/j.therap.2025.04.005","url":null,"abstract":"<div><h3>Introduction</h3><div>Patient satisfaction is a key element in medical practice. Few studies have investigated patient satisfaction or dissatisfaction with their drug treatment.</div></div><div><h3>Method</h3><div>Using the World Health Organization (WHO) global pharmacovigilance<span> database, we investigated, through disproportionality analyses, potential associations between exposure to drugs and “patient dissatisfaction with treatment” reports. All reports of “patient dissatisfaction with treatment” in adults until 31/12/2024 were included.</span></div></div><div><h3>Results/discussion</h3><div><span>Results are expressed as reporting odds ratio (ROR). Among 506 reports, three quarters came from consumers, involving mainly women aged between 45 and 64. The main coreported term was drug inefficacy (before adverse drug reactions). The first anatomical therapeutic chemical (ATC) group was dermatological drugs (25.5%) followed by alimentary tract and metabolism (24.3%), nervous system (22.5%) drugs. A significant association was found with 22 drugs with the highest ROR values for plecanatide, </span>efinaconazole and avatrombopag.</div></div><div><h3>Conclusion</h3><div>Despite its mandatory limitations (underreporting, selective reporting…), this study shows that pharmacovigilance data could help to understand some aspects of social pharmacology, here, patient dissatisfaction with their drug treatment.</div></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"80 6","pages":"Pages 667-672"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions of contribution of the placebo effects to drug efficacy in community pharmacy practice: A cross-sectional survey","authors":"Joey Fournier ,&nbsp;Leo Druart ,&nbsp;Marie Allier ,&nbsp;Matthieu Roustit","doi":"10.1016/j.therap.2025.02.015","DOIUrl":"10.1016/j.therap.2025.02.015","url":null,"abstract":"<div><h3>Introduction</h3><div>The placebo effect, a well-documented phenomenon in clinical practice, remains complex and multifaceted. While the perception of placebo effects has been assessed among various healthcare professionals, pharmacists — recognized experts in treatment effects and effectiveness — have not been specifically studied. This cross-sectional study aimed to evaluate the knowledge and perceptions of healthcare professionals working in community pharmacies in France, Switzerland, and Belgium regarding placebo effects.</div></div><div><h3>Material and methods</h3><div>A self-administered questionnaire was distributed to pharmacists, pharmacy technicians, and community pharmacy students between September and December 2023. The questionnaire used numeric scales (0–10) to evaluate knowledge of placebo effects, underlying mechanisms, influencing factors, and demographic details.</div></div><div><h3>Results</h3><div>A total of 377 responses were collected, primarily from female pharmacists practicing in France. Respondents demonstrated a strong theoretical understanding of placebo effects (<em>n</em> <!-->=<!--> <!-->302; 80%). Among 12 proposed contextual factors influencing placebo effects, the three most highly rated were patient-related: patient expectations and preferences, past experiences, and beliefs or representations about their condition. Perceptions of placebo effects varied significantly according to medication type, with median scores of 1 [0–3] for treatments with demonstrated efficacy, 3 [1–5] for conventional medicines without demonstrated efficacy, and 6 [4–9] for complementary and alternative medicines (CAM). This suggests that placebo-related efficacy is perceived as more associated with the type of medication (e.g., CAM vs. conventional medicines) rather than the presence or absence of demonstrated efficacy.</div></div><div><h3>Conclusion</h3><div>Pharmacists showed a solid theoretical grasp of placebo effects but seem to associate placebo-related efficacy more strongly with medication type than evidence of efficacy. These findings highlight the need to raise awareness among pharmacy-based healthcare professionals about treatment efficacy to improve clinical practice and patient care.</div></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"80 6","pages":"Pages 689-695"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}